Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06589440 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
A Phase 2 study of Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), sponsored by Stingray Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 6
- Study locations
NCT06589440 is a Phase 2 study of Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) that is actively recruiting participants, run by Stingray Therapeutics. The registered enrollment target is 70 participants. The trial reports 6 study locations across 3 states.
The verdict
NCT06589440, a Phase 2 study of Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), is actively recruiting participants, sponsored by Stingray Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.
Conditions Studied
Interventions
- DRUG SR-8541A
Study Locations (6)
Texas
- Texas Oncology- Austin - Austin
- Texas Oncology- Sammons- DFW - Dallas
- The University of Texas M.D. Anderson Cancer Center GI Medical Oncology Dept - Houston
- Texas Oncology- Northeast Texas - Tyler
New Jersey
- Atlantic Health - Morristown
Washington
- Swedish - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06589440
The ClinicalTrials.gov registry entry for NCT06589440 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stingray Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) appearing as the primary indexed condition, and to 1 intervention - of which SR-8541A is the first listed.
NCT06589440 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Texas, New Jersey, Washington.
Frequently Asked Questions
What is clinical trial NCT06589440 about?
NCT06589440 is a clinical study titled "Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)". This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.
What is the current status of trial NCT06589440?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2024-11-20. Estimated completion is 2027-09.
What conditions does trial NCT06589440 study?
This clinical trial studies the following conditions: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC).
What interventions are being tested in trial NCT06589440?
The interventions under investigation include: SR-8541A (DRUG).
Who is sponsoring clinical trial NCT06589440?
This trial is sponsored by Stingray Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06589440 being conducted?
This trial has 6 study locations across New Jersey, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.